Avrukibart vs guselkumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

Avrukibart

Developed by Oruka Therapeutics

Phase 2 in Psoriasismonoclonal antibody
Partial signal

NCT07090330 · Phase 2 · active, not recruiting

This was a randomized, double-blind Phase 2 trial with 80 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-04-27. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.

Next expected readout: May 2030 · NCT07449702 (registry estimate)

Reported efficacy

Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16: Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). (met)

Result source: NCT07090330

guselkumab · Tremfya

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02203032 · Phase 3 · completed

In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.

Next expected readout: December 2026 · NCT05004727 (registry estimate)

Reported efficacy

Number of Visits at Which Participants Achieved an Investigator's Global Assessment (IGA) Response of Cleared (0) or Minimal (1) and at Least a 2 Grade Improvement (From Week 16) From Week 28 Through Week 40: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001. (met)

Result source: NCT02203032

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAvrukibartguselkumab
PASI 75—Not reported84.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323
PASI 90—Not reported70% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323
PASI 100—Not reported50% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323
sPGA 0/1—Not reported85.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
DLQI, change—Not reported-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599

PASI 75

Avrukibart
—Not reported
guselkumab
84.1% vs 6.3%+77.8 vs placebo100 mg · wk 16 · n 63NCT02325219
11 other results
  • 89.2% vs 6.3% 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • 86.3% vs 68.5% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 92.7% vs 92.8% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 89.3% vs 91.6% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 91.2% vs 73.1% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 78.6% vs 4.8% 100 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 50 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 81% vs 4.8% 200 mg · wk 16 · n 42 · Phase 2 · secondary NCT01483599
  • 75.6% vs 4.8% 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 43.9% vs 4.8% 5 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • 5.1% vs 22.9% wk 2 · n 507 · Phase 4 · secondary NCT03573323

PASI 90

Avrukibart
—Not reported
guselkumab
70% vs 2.4%+67.6 vs placebo100 mg · wk 16 · n 496NCT02207244
10 other results
  • 73.3% vs 2.9% wk 16 · n 329 · Phase 3 · primary NCT02207231
  • 69.8% vs 0% 100 mg · wk 16 · n 63 · Phase 3 · primary NCT02325219
  • 70.8% vs 0% 50 mg · wk 16 · n 65 · Phase 3 · primary NCT02325219
  • 75.8% vs 0% wk 16 · n 62 · Phase 3 · primary NCT02905331
  • 70% vs 46.8% 100 mg · wk 16 · n 496 · Phase 3 · secondary NCT02207244
  • 78.5% vs 79.6% 100 mg · wk 16 · n 534 · Phase 3 · secondary NCT03090100
  • 69.1% vs 76.1% 100 mg · wk 12 · n 534 · Phase 3 · secondary NCT03090100
  • 73.3% vs 49.7% wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • 35.9% vs 58.5% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 7.9% vs 21% wk 4 · n 507 · Phase 4 · secondary NCT03573323

PASI 100

Avrukibart
—Not reported
guselkumab
50% vs 0%+50 vs placebowk 16 · n 62NCT02905331
3 other results
  • 24.9% vs 41.3% wk 12 · n 507 · Phase 4 · primary NCT03573323
  • 13.6% vs 29.6% wk 8 · n 507 · Phase 4 · secondary NCT03573323
  • 1.4% vs 6.7% wk 4 · n 507 · Phase 4 · secondary NCT03573323

sPGA 0/1

Avrukibart
—Not reported
guselkumab
85.7% vs 7.1%+78.6 vs placebo100 mg · wk 16 · n 42NCT01483599
4 other results
  • 78.6% vs 7.1% 50 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 83.3% vs 7.1% 200 mg · wk 16 · n 42 · Phase 2 · primary NCT01483599
  • 61% vs 7.1% 15 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599
  • 34.1% vs 7.1% 5 mg · wk 16 · n 41 · Phase 2 · primary NCT01483599

DLQI, change

Avrukibart
—Not reported
guselkumab
-11.2 vs -2.6−8.6 vs placebo100 mg · wk 16 · n 495NCT02207244
10 other results
  • -11.2 vs -0.6 wk 16 · n 329 · Phase 3 · secondary NCT02207231
  • -8.5 vs -0.8 100 mg · wk 16 · n 63 · Phase 3 · secondary NCT02325219
  • -7 vs -0.4 100 mg · wk 8 · n 63 · Phase 3 · secondary NCT02325219
  • -8.3 vs -0.8 50 mg · wk 16 · n 65 · Phase 3 · secondary NCT02325219
  • -7.5 vs -0.4 50 mg · wk 8 · n 65 · Phase 3 · secondary NCT02325219
  • -10.8 vs -2.3 100 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.1 vs -2.3 50 mg · wk 16 · n 40 · Phase 2 · secondary NCT01483599
  • -11.4 vs -2.3 200 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  • -10.3 vs -2.3 15 mg · wk 16 · n 41 · Phase 2 · secondary NCT01483599
  • -6.2 vs -2.3 5 mg · wk 16 · n 39 · Phase 2 · secondary NCT01483599
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Avrukibart
Primary endpoint PASI 100 at week 16 (interim analysis): 63.5% (40/63) with ORKA-001 vs 1 of 21 with placebo (2026-04-27). NCT07090330 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Avrukibart: 0 of 4 rows · guselkumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricguselkumab
Dropout rate
—100 mga
NCT02203032 · Phase 3
show 42 more results
3.6%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
1.6%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
9.5%
NCT03573323 · Phase 4 · registry result, not featured evidence
13%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
4.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
7.6%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
3.1%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
5.1%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
4.8%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—100 mga
NCT02203032 · Phase 3
show 42 more results
1.8%100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207244 · Phase 3
—100 mg
NCT02207231 · Phase 3
—100 mg
NCT02207231 · Phase 3
0%Guselkumab
NCT02905331 · Phase 3
—Guselkumab (Week 0-16)
NCT02905331 · Phase 3
—Guselkumab (Week 16-40)
NCT02905331 · Phase 3
1.6%
NCT03573323 · Phase 4 · registry result, not featured evidence
1.3%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
1.9%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
—Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
—Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
1.7%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
—100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
2.4%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
9.5%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
Serious AEs
6.7%100 mga
NCT02203032 · Phase 3
show 42 more results
1.6%100 mg
NCT02207244 · Phase 3
2.1%100 mg
NCT02207244 · Phase 3
14%100 mg
NCT02207244 · Phase 3
2.5%100 mg
NCT02207231 · Phase 3
2.4%100 mg
NCT02207231 · Phase 3
—Guselkumab
NCT02905331 · Phase 3
3.2%Guselkumab (Week 0-16)
NCT02905331 · Phase 3
1.6%Guselkumab (Week 16-40)
NCT02905331 · Phase 3
3.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
3.9%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
3.7%100 mg
NCT05272150 · Phase 3 · registry result, not featured evidence
5.3%100 mg
NCT06039189 · Phase 3 · registry result, not featured evidence
4.7%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.3%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
2.2%100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
3.5%100 mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4.3%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q8W
NCT03818035 · Phase 3 · registry result, not featured evidence
0%100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
—100mg
NCT03818035 · Phase 3 · registry result, not featured evidence
4%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
6.6%100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
—100 mg Q16W
NCT03818035 · Phase 3 · registry result, not featured evidence
9.7%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.6%100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
9.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
1.5%50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
5%Part I/IIa (Week 0 to Week 32): Gu
NCT02951533 · Phase 3 · registry result, not featured evidence
0%Part III (Week 64 Through Week 100
NCT02951533 · Phase 3 · registry result, not featured evidence
5.5%Part IIb (Week 32 Through Week 56)
NCT02951533 · Phase 3 · registry result, not featured evidence
6.2%100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
5%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
7.1%50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
5.3%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mga
nasopharyngitis 17%
upper respiratory tract infection 11.1%
NCT02203032 · Phase 3
show 37 more results
100 mg
nasopharyngitis 7.1% (placebo 6.5%)
headache 5.1% (placebo 2.8%)
upper respiratory tract infection 3.2% (placebo 4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 3.7% (placebo 6.5%)
upper respiratory tract infection 2.5% (placebo 4%)
arthralgia 1.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 30% (placebo 6.5%)
upper respiratory tract infection 23.5% (placebo 4%)
arthralgia 9.7% (placebo 2.4%)
NCT02207244 · Phase 3
100 mg
nasopharyngitis 20.1% (placebo 9.8%)
upper respiratory tract infection 9.6% (placebo 5.2%)
gastroenteritis 3.4% (placebo 1.1%)
NCT02207231 · Phase 3
100 mg
nasopharyngitis 9.1% (placebo 9.8%)
upper respiratory tract infection 7.6% (placebo 5.2%)
headache 4.3% (placebo 4%)
NCT02207231 · Phase 3
injection site pain 40.3% (placebo 43.8%)
injection site coldness 22.6% (placebo 18.8%)
injection site pruritus 12.9% (placebo 12.5%)
NCT02905331 · Phase 3
injection site pain 18% (placebo 43.8%)
injection site coldness 11.5% (placebo 18.8%)
viral upper respiratory tract infection 9.8% (placebo 0%)
NCT02905331 · Phase 3
upper respiratory tract infection 8.1%
nasopharyngitis 5.3%
injection site reaction 1.2%
NCT03573323 · Phase 4 · registry result, not featured evidence
100 mg
upper respiratory tract infection 16.9% (placebo 3.8%)
nasopharyngitis 11.7% (placebo 3.8%)
covid-19 6.5% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 24.7% (placebo 3.8%)
covid-19 16% (placebo 0%)
arthralgia 7.4% (placebo 0%)
NCT05272150 · Phase 3 · registry result, not featured evidence
100 mg
upper respiratory tract infection 15.1% (placebo 2.7%)
nasopharyngitis 6.7% (placebo 7.1%)
covid-19 4.4% (placebo 0.9%)
NCT06039189 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 17.6%
headache 5.4%
back pain 4.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
nasopharyngitis 18.5%
hypertension 5.9%
arthralgia 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q8W
covid-19 14.7%
nasopharyngitis 12.5%
psoriasis 7.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 14.1%
covid-19 9.3%
headache 5.7%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nasopharyngitis 24.3%
headache 9%
hypertension 5.5%
NCT03818035 · Phase 3 · registry result, not featured evidence
100mg
nail psoriasis 22.2%
back pain 11.1%
covid-19 11.1%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 15.4%
headache 6%
back pain 5.4%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg Q16W
nasopharyngitis 12.4%
covid-19 8.8%
psoriasis 8.8%
NCT03818035 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 50% (placebo 10.9%)
eczema 11.3% (placebo 1.6%)
injection site erythema 11.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 12.7% (placebo 10.9%)
dental caries 3.2% (placebo 1.6%)
upper respiratory tract infection 3.2% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 60.3% (placebo 10.9%)
arthralgia 14.3% (placebo 0%)
influenza 14.3% (placebo 1.6%)
NCT02325219 · Phase 3 · registry result, not featured evidence
50 mg
nasopharyngitis 21.5% (placebo 10.9%)
alopecia 3.1% (placebo 0%)
arthralgia 3.1% (placebo 0%)
NCT02325219 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.7%
headache 15%
diarrhoea 11.7%
NCT02951533 · Phase 3 · registry result, not featured evidence
aspartate aminotransferase increased 2.8%
tooth infection 2.8%
abdominal discomfort 0%
NCT02951533 · Phase 3 · registry result, not featured evidence
nasopharyngitis 50.9%
bronchitis 9.1%
alanine aminotransferase increased 5.5%
NCT02951533 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 22.1%
upper respiratory tract infection 15.5%
headache 9%
NCT03090100 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 10% (placebo 2.4%)
upper respiratory tract infection 7.5% (placebo 2.4%)
back pain 5% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
100 mg
back pain 4.8% (placebo 0%)
headache 4.8% (placebo 2.4%)
sinusitis 4.8% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
nasopharyngitis 17.9% (placebo 2.4%)
back pain 2.6% (placebo 0%)
headache 2.6% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
50 mg
hypertension 7.1% (placebo 2.4%)
fatigue 4.8% (placebo 7.1%)
arthralgia 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 13.2% (placebo 2.4%)
cough 5.3% (placebo 2.4%)
upper respiratory tract infection 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
200 mg
upper respiratory tract infection 7.3% (placebo 2.4%)
cough 4.9% (placebo 2.4%)
nasopharyngitis 4.9% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
back pain 2.4% (placebo 0%)
nasopharyngitis 2.4% (placebo 2.4%)
sinusitis 2.4% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
15 mg
headache 9.8% (placebo 2.4%)
nasopharyngitis 9.8% (placebo 2.4%)
back pain 2.4% (placebo 0%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 15.8% (placebo 2.4%)
upper respiratory tract infection 10.5% (placebo 2.4%)
arthralgia 5.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 14.6% (placebo 2.4%)
back pain 7.3% (placebo 0%)
headache 7.3% (placebo 2.4%)
NCT01483599 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

guselkumab

IGA 0 1 Response Visits 1.5 vs 0.7 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
PASI90 Response Visits 2.2 vs 1.1 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0 Response Visits 0.9 vs 0.4 Ustekinumab visits
event count · visits
NCT02203032 · Phase 3
IGA 0/1 84.1% (n=496) vs 8.5% (n=248) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 13 more results
83.5% (n=496) vs 64.9% (n=248) Adalimumab @ 24wk100 mg
NCT02207244 · Phase 3
84.1% (n=496) vs 67.7% (n=248) Adalimumab @ 16wk100 mg
NCT02207244 · Phase 3
88.9% (n=63) vs 7.8% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
85% (n=534) vs 74.9% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
86.7% (n=534) vs 86.6% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
85.6% (n=534) vs 86.4% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.3% (n=65) vs 7.8% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
31.1% (n=135) vs 14.3% (n=133) Ustekinumab @ 28wk
NCT02203032 · Phase 3
85.1% (n=329) vs 6.9% (n=174) placebo @ 16wk
NCT02207231 · Phase 3
84.2% (n=329) vs 61.7% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
80.5% (n=329) vs 55.4% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
85.1% (n=329) vs 65.9% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
80.6% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
PASI 90 70% (n=496) vs 2.4% (n=248) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 17 more results
75.2% (n=496) vs 54.8% (n=248) Adalimumab @ 24wk100 mg
NCT02207244 · Phase 3
70% (n=496) vs 46.8% (n=248) Adalimumab @ 16wk100 mg
NCT02207244 · Phase 3
69.8% (n=63) vs 0% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
84.5% (n=534) vs 70% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
69.1% (n=534) vs 76.1% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
78.5% (n=534) vs 79.6% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
70.8% (n=65) vs 0% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
73.3% (n=329) vs 2.9% (n=174) placebo @ 16wk
NCT02207231 · Phase 3
80.2% (n=329) vs 53% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
76.3% (n=329) vs 47.9% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
73.3% (n=329) vs 49.7% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
75.8% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
7.9% (n=507) vs 21% (n=520) Ixekizumab @ 4wk
NCT03573323 · Phase 4 · registry result, not featured evidence
35.9% (n=507) vs 58.5% (n=520) Ixekizumab @ 8wk
NCT03573323 · Phase 4 · registry result, not featured evidence
81.7% (n=60) vs 13.6% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
90.7% (n=54) vs 50% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
78.3% (n=60) vs 11.9% (n=59) Fumaric Acid Esters @ 32wk
NCT02951533 · Phase 3 · registry result, not featured evidence
IGA 0 51.8% (n=496) vs 31.5% (n=248) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 5 more results
62.2% (n=534) vs 50.4% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
52.6% (n=329) vs 29.3% (n=334) Adalimumab @ 24wk
NCT02207231 · Phase 3
50.5% (n=329) vs 25.7% (n=334) Adalimumab @ 48wk
NCT02207231 · Phase 3
56.5% (n=62) vs 0% (n=16) placebo @ 16wk
NCT02905331 · Phase 3
51.7% (n=60) vs 6.8% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
PASI 90 Response Maintenance 72.3% (n=534) vs 64.4% (n=514) Secukinumab @ 48wk100 mg
responder rate · % of participants
NCT03090100 · Phase 3 · registry result, not featured evidence
show 5 more results
71% (n=534) vs 61.5% (n=514) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.1% (n=419) vs 80.9% (n=409) Secukinumab @ 48wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
81.8% (n=193) vs 35.4% (n=181) placebo @ 48wk
NCT02207244 · Phase 3
86% (n=193) vs 11.5% (n=181) placebo @ 72wk
NCT02207244 · Phase 3
85.2% (n=54) vs 35.7% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
DLQI -11.23 vs -2.6 placebo score @ 16wk100 mg
absolute change · score
NCT02207244 · Phase 3
show 11 more results
-8.5 vs -0.8 placebo score @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-7 vs -0.4 placebo score @ 8wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-10.8 vs -2.3 placebo score @ 16wk100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-8.3 vs -0.8 placebo score @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-7.5 vs -0.4 placebo score @ 8wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
-11.1 vs -2.3 placebo score @ 16wk50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-11.4 vs -2.3 placebo score @ 16wk200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-10.3 vs -2.3 placebo score @ 16wk15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-6.2 vs -2.3 placebo score @ 16wk5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
-11.2 vs -0.6 placebo score @ 16wk
NCT02207231 · Phase 3
-15.2 vs -9.4 Fumaric Acid Esters score @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
PASI 75 86.3% (n=496) vs 68.5% (n=248) Adalimumab @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 14 more results
84.1% (n=63) vs 6.3% (n=64) placebo @ 16wk100 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
89.3% (n=534) vs 91.6% (n=514) Secukinumab @ 12wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
92.7% (n=534) vs 92.8% (n=514) Secukinumab @ 16wk100 mg
NCT03090100 · Phase 3 · registry result, not featured evidence
78.6% (n=42) vs 4.8% (n=42) placebo @ 16wk100 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
89.2% (n=65) vs 6.3% (n=64) placebo @ 16wk50 mg
NCT02325219 · Phase 3 · registry result, not featured evidence
81% (n=42) vs 4.8% (n=42) placebo @ 16wk50 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
81% (n=42) vs 4.8% (n=42) placebo @ 16wk200 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
75.6% (n=41) vs 4.8% (n=42) placebo @ 16wk15 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
43.9% (n=41) vs 4.8% (n=42) placebo @ 16wk5 mg
NCT01483599 · Phase 2 · registry result, not featured evidence
91.2% (n=329) vs 73.1% (n=334) Adalimumab @ 16wk
NCT02207231 · Phase 3
5.1% (n=507) vs 22.9% (n=520) Ixekizumab @ 2wk
NCT03573323 · Phase 4 · registry result, not featured evidence
90% (n=60) vs 27.1% (n=59) Fumaric Acid Esters @ 24wk
NCT02951533 · Phase 3 · registry result, not featured evidence
98.1% (n=54) vs 64.3% (n=14) Fumaric Acid Esters @ 56wk
NCT02951533 · Phase 3 · registry result, not featured evidence
90% (n=60) vs 23.7% (n=59) Fumaric Acid Esters @ 32wk
NCT02951533 · Phase 3 · registry result, not featured evidence
Ss-IGA 0 1 80.6% (n=408) vs 10.9% (n=202) placebo @ 16wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
83.4% (n=277) vs 14.5% (n=145) placebo @ 16wk
NCT02207231 · Phase 3
PSSD Symptom -40.4 vs -8.3 placebo score @ 16wk100 mg
absolute change · score
NCT02207244 · Phase 3
show 1 more result
-41.9 vs -3 placebo score @ 16wk
NCT02207231 · Phase 3
PSSD Symptom Score 0 35.1% (n=410) vs 22.5% (n=200) Adalimumab @ 24wk100 mg
responder rate · % of participants
NCT02207244 · Phase 3
show 1 more result
36.3% (n=248) vs 21.6% (n=273) Adalimumab @ 24wk
NCT02207231 · Phase 3

+ 99 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Avrukibart's landscape · guselkumab's landscape